Insider Transactions in Q1 2023 at Ionis Pharmaceuticals Inc (IONS)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 28
2023
|
C Frank Bennett EVP, Chief Scientific Officer |
BUY
Other acquisition or disposition
|
Direct |
383
+0.54%
|
$11,490
$30.52 P/Share
|
|
Feb 28
2023
|
Elizabeth L Hougen EVP, Finance & CFO |
BUY
Other acquisition or disposition
|
Direct |
163
+0.22%
|
$4,890
$30.52 P/Share
|
|
Feb 28
2023
|
Richard S Geary EVP, Chief Development Officer |
BUY
Other acquisition or disposition
|
Direct |
575
+0.78%
|
$17,250
$30.52 P/Share
|
|
Feb 28
2023
|
Patrick R. O'Neil EVP CLO & General Counsel |
BUY
Other acquisition or disposition
|
Direct |
301
+0.71%
|
$9,030
$30.52 P/Share
|
|
Feb 28
2023
|
Eric Swayze EVP Research |
BUY
Other acquisition or disposition
|
Direct |
575
+1.74%
|
$17,250
$30.52 P/Share
|
|
Feb 06
2023
|
C Frank Bennett EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,813
-2.54%
|
$72,520
$40.57 P/Share
|
|
Feb 06
2023
|
Onaiza Cadoret Manier EVP, Chf GL Pdt Str & Oper Ofc |
SELL
Open market or private sale
|
Direct |
1,451
-6.4%
|
$58,040
$40.66 P/Share
|
|
Feb 06
2023
|
Richard S Geary EVP, Chief Development Officer |
SELL
Open market or private sale
|
Direct |
1,920
-2.58%
|
$76,800
$40.66 P/Share
|
|
Feb 06
2023
|
Elizabeth L Hougen EVP, Finance & CFO |
SELL
Open market or private sale
|
Direct |
2,079
-2.68%
|
$83,160
$40.59 P/Share
|
|
Feb 06
2023
|
Brett P Monia Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
24,651
-14.5%
|
$986,040
$40.69 P/Share
|
|
Feb 06
2023
|
Patrick R. O'Neil EVP CLO & General Counsel |
SELL
Open market or private sale
|
Direct |
1,920
-4.41%
|
$76,800
$40.86 P/Share
|
|
Feb 06
2023
|
Eugene Schneider EVP, Chf Clinical Develop Ofcr |
SELL
Open market or private sale
|
Direct |
1,413
-5.36%
|
$56,520
$40.67 P/Share
|
|
Feb 06
2023
|
Eric Swayze EVP Research |
SELL
Open market or private sale
|
Direct |
1,815
-5.38%
|
$72,600
$40.79 P/Share
|
|
Feb 03
2023
|
C Frank Bennett EVP, Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,609
+4.81%
|
-
|
|
Feb 03
2023
|
Onaiza Cadoret Manier EVP, Chf GL Pdt Str & Oper Ofc |
BUY
Grant, award, or other acquisition
|
Direct |
4,140
+15.44%
|
-
|
|
Feb 03
2023
|
Richard S Geary EVP, Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,822
+4.89%
|
-
|
|
Feb 03
2023
|
Elizabeth L Hougen EVP, Finance & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
4,140
+5.07%
|
-
|
|
Feb 03
2023
|
Brett P Monia Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
49,093
+9.5%
|
-
|
|
Feb 03
2023
|
Patrick R. O'Neil EVP CLO & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
3,822
+8.08%
|
-
|
|
Feb 03
2023
|
Eugene Schneider EVP, Chf Clinical Develop Ofcr |
BUY
Grant, award, or other acquisition
|
Direct |
4,033
+13.27%
|
-
|
|
Feb 03
2023
|
Eric Swayze EVP Research |
BUY
Grant, award, or other acquisition
|
Direct |
3,715
+9.91%
|
-
|
|
Jan 31
2023
|
Patrick R. O'Neil EVP CLO & General Counsel |
SELL
Open market or private sale
|
Direct |
4,500
-10.19%
|
$175,500
$39.71 P/Share
|
|
Jan 30
2023
|
Patrick R. O'Neil EVP CLO & General Counsel |
SELL
Open market or private sale
|
Direct |
4,500
-9.24%
|
$175,500
$39.42 P/Share
|
|
Jan 18
2023
|
Onaiza Cadoret Manier EVP, Chf GL Pdt Str & Oper Ofc |
SELL
Open market or private sale
|
Direct |
3,748
-16.82%
|
$146,172
$39.55 P/Share
|
|
Jan 18
2023
|
Richard S Geary EVP, Chief Development Officer |
SELL
Open market or private sale
|
Direct |
7,873
-10.05%
|
$307,047
$39.57 P/Share
|
|
Jan 18
2023
|
Elizabeth L Hougen EVP, Finance & CFO |
SELL
Open market or private sale
|
Direct |
8,280
-10.13%
|
$322,920
$39.7 P/Share
|
|
Jan 18
2023
|
Brett P Monia Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
25,066
-17.18%
|
$977,574
$39.49 P/Share
|
|
Jan 18
2023
|
Patrick R. O'Neil EVP CLO & General Counsel |
SELL
Open market or private sale
|
Direct |
7,836
-13.87%
|
$305,604
$39.49 P/Share
|
|
Jan 18
2023
|
Eugene Schneider EVP, Chf Clinical Develop Ofcr |
SELL
Open market or private sale
|
Direct |
4,752
-17.55%
|
$185,328
$39.57 P/Share
|
|
Jan 18
2023
|
Eric Swayze EVP Research |
SELL
Open market or private sale
|
Direct |
5,631
-15.79%
|
$219,609
$39.74 P/Share
|
|
Jan 18
2023
|
Joseph Baroldi EVP, Chief Business Officer |
SELL
Open market or private sale
|
Indirect |
375
-30.59%
|
$14,625
$39.79 P/Share
|
|
Jan 18
2023
|
C Frank Bennett EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
6,978
-9.32%
|
$265,164
$38.89 P/Share
|
|
Jan 17
2023
|
Onaiza Cadoret Manier EVP, Chf GL Pdt Str & Oper Ofc |
BUY
Exercise of conversion of derivative security
|
Direct |
10,197
+31.39%
|
-
|
|
Jan 17
2023
|
Richard S Geary EVP, Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
21,983
+21.91%
|
-
|
|
Jan 17
2023
|
Elizabeth L Hougen EVP, Finance & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
23,154
+22.08%
|
-
|
|
Jan 17
2023
|
Brett P Monia Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
57,267
+28.18%
|
-
|
|
Jan 17
2023
|
Patrick R. O'Neil EVP CLO & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
21,871
+27.9%
|
-
|
|
Jan 17
2023
|
Eugene Schneider EVP, Chf Clinical Develop Ofcr |
BUY
Exercise of conversion of derivative security
|
Direct |
13,046
+32.51%
|
-
|
|
Jan 17
2023
|
Eric Swayze EVP Research |
BUY
Exercise of conversion of derivative security
|
Direct |
15,780
+30.67%
|
-
|
|
Jan 17
2023
|
Joseph Baroldi EVP, Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Indirect |
904
+42.44%
|
-
|
|
Jan 17
2023
|
C Frank Bennett EVP, Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
19,417
+20.6%
|
-
|
|
Jan 17
2023
|
Joseph Klein Iii Director |
SELL
Open market or private sale
|
Direct |
2,000
-10.64%
|
$80,000
$40.0 P/Share
|